Karyopharm Therapeutics Inc

詳細情報 Karyopharm Therapeutics Inc 企業名

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, oral SINE compound that, like selinexor, selectively blocks the nuclear export protein XPO1.

企業情報

企業コードKPTI

会社名Karyopharm Therapeutics Inc

上場日Nov 06, 2013

最高経営責任者「CEO」Mr. Richard A. Paulson

従業員数279

証券種類Ordinary Share

決算期末Nov 06

本社所在地85 Wells Avenue

都市NEWTON

証券取引所NASDAQ Global Select Consolidated

国United States of America

郵便番号02459

電話番号16176580600

ウェブサイトhttps://karyopharm.com/

企業コードKPTI

上場日Nov 06, 2013

最高経営責任者「CEO」Mr. Richard A. Paulson

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Michael Mano, J.D.

Senior Vice President, General Counsel, Secretary

11.90K

-19.01%

Mr. Stuart Poulton

Executive Vice President, Chief Development Officer

8.12K

-2.30%

Dr. Reshma Rangwala, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

6.71K

-28.64%

Mr. Barry E. Greene

Lead Independent Director

907.00

--

Ms. Sohanya Cheng

Executive Vice President, Chief Commercial Officer

--

Mr. Garen G. Bohlin

Independent Director

--

Mr. Chen Schor, CPA

Independent Director

--

Mr. Richard A. Paulson

President, Chief Executive Officer, Director

--

Mr. Brendan Strong

Senior Vice President - Investor Relations and Corporate Communications

--

Dr. Mansoor Raza Mirza, M.D.

Independent Director and Clinical Consultant

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Mr. Michael Mano, J.D.

Senior Vice President, General Counsel, Secretary

11.90K

-19.01%

Mr. Stuart Poulton

Executive Vice President, Chief Development Officer

8.12K

-2.30%

Dr. Reshma Rangwala, M.D., Ph.D.

Executive Vice President, Chief Medical Officer

6.71K

-28.64%

Mr. Barry E. Greene

Lead Independent Director

907.00

--

Ms. Sohanya Cheng

Executive Vice President, Chief Commercial Officer

--

Mr. Garen G. Bohlin

Independent Director

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Fri, May 16

株主統計

種類

株主統計

比率

The Vanguard Group, Inc.

5.91%

J. Wood Capital Advisors LLC

5.30%

Adage Capital Management, L.P.

4.88%

Palo Alto Investors LP

3.75%

Eversept Partners, LP

2.98%

Other

77.19%

株主統計

比率

The Vanguard Group, Inc.

5.91%

J. Wood Capital Advisors LLC

5.30%

Adage Capital Management, L.P.

4.88%

Palo Alto Investors LP

3.75%

Eversept Partners, LP

2.98%

Other

77.19%

種類

株主統計

比率

Hedge Fund

18.53%

Investment Advisor

13.01%

Corporation

5.30%

Research Firm

4.94%

Investment Advisor/Hedge Fund

4.53%

Venture Capital

1.80%

Individual Investor

1.11%

Pension Fund

0.05%

Other

50.74%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

284

4.26M

49.27%

-1.69M

2025Q1

308

4.25M

49.43%

-1.53M

2024Q4

324

4.68M

55.67%

-1.51M

2024Q3

341

4.98M

60.06%

-2.16M

2024Q2

356

5.56M

67.54%

-2.08M

2024Q1

352

5.60M

72.46%

-1.99M

2023Q4

354

5.60M

73.31%

-2.02M

2023Q3

365

5.88M

77.33%

-1.69M

2023Q2

380

6.19M

81.48%

-2.04M

2023Q1

395

6.56M

86.55%

-1.62M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

The Vanguard Group, Inc.

510.29K

5.91%

-5.00

-0.00%

Mar 31, 2025

J. Wood Capital Advisors LLC

458.13K

5.3%

--

Apr 10, 2025

Adage Capital Management, L.P.

421.32K

4.88%

-1.00

-0.00%

Mar 31, 2025

Palo Alto Investors LP

324.03K

3.75%

-3.10K

-0.95%

Mar 31, 2025

Eversept Partners, LP

257.15K

2.98%

+117.90K

+84.67%

Mar 31, 2025

Citadel Advisors LLC

206.91K

2.39%

-2.00

-0.00%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

188.02K

2.18%

-1.00K

-0.53%

Mar 31, 2025

Catalio Capital Management, LP

155.62K

1.8%

-3.00

-0.00%

Mar 31, 2025

J.P. Morgan Securities LLC

147.42K

1.71%

+129.01K

+700.61%

Mar 31, 2025

T. Rowe Price Investment Management, Inc.

139.65K

1.62%

+139.65K

--

Mar 31, 2025

詳細を見る

3.911USD

Karyopharm Therapeutics Inc

3.911

概要

企業名

金融